



Fred Hutchinson Cancer Research Center Deploys GenoLogics' Proteomics Purposed Software Solution to Accelerate Their Cancer Biomarker Discovery

Proteus™ is chosen by leading edge research center for proteomics research

Victoria, B.C. — April 25, 2006 – GenoLogics Life Sciences Software Inc. (GenoLogics) today announced that Fred Hutchinson Cancer Research Center chose Proteus™, GenoLogics' proteomics purposed lab and data management solution, to use in its cancer biomarker discovery research in early detection of ovarian cancer. GenoLogics worked with the Hutchinson Center to integrate Proteus with the Center's recently released Computational Proteomics Analysis System (CPAS) data repository.

Proteus will be used in the lab of Dr. Martin McIntosh, associate member of the Public Health Sciences Division at the Hutchinson Center and principal investigator of the Center's Computational Proteomics Laboratory (CPL). The CPL develops and uses computational approaches for protein and proteomics research.

"We were looking for a scientific data management solution based on open standards that could help us share and disseminate data with other leading cancer centers around the world in an eXperiment ARchive format (XAR)," McIntosh commented. "GenoLogics' Proteus met these requirements."

Proteus is the only data management solution that can export a complete proteomics experiment XAR data file, based on the FuGE (Functional Genomics Experiment) object model with proteomics extensions, and import the file into the lab's open source Computational Proteomics and Analysis System (CPAS) data repository. CPAS is used to manage the CPL containing over 75 million putative MS2 peptides, growing at 1 million per week. The National Cancer Institute and the Canary Foundation funded the development of CPAS.

Several cancer research institutes nationally and internationally have joined with the Hutchinson Center to form an International Cancer Biomarker Consortium (ICBC) with a goal to improve discovery methods and identify biomarkers. Michael Ball, CEO of GenoLogics stated, "We believe the ICBC is an important initiative and we fully support the goals of this consortium. GenoLogics is a founding member of the ICBC Informatics Working Group and we look forward to working with the Hutchinson Center and ICBC to advance early detection cancer research."

About GenoLogics

GenoLogics is the leading provider of an open integrating platform and bioinformatics solutions that help life science and pharmaceutical laboratories, specializing in the field of proteomics and systems biology research, to manage, integrate and analyze enormous volumes of scientific and lab data to advance health science research and drug discovery. The company's mission is to provide solutions to accelerate the prevention and cure of diseases such as cancer. For more information, visit www.genologics.com.

About Fred Hutchinson Cancer Center

Fred Hutchinson Cancer Research Center has interdisciplinary teams of world-renowned scientists and humanitarians that work together to prevent, diagnose and treat cancer, HIV/AIDS and other diseases. Its researchers, including three Nobel laureates, bring a relentless pursuit and passion for health, knowledge and hope to their work and to the world. For more information, please visit www.fhcr.org or <http://proteomics.fhcr.org>

Contact

GenoLogics Life Sciences Software Inc.
Media Relations: Tanis MacSween
Tel: 250-483-7063
Email: tanis.macsween@genologics.com